交易中 09-20 12:41:50 美东时间
-0.060
-2.30%
Allarity Therapeutics (NASDAQ:ALLR) on Friday announced the appointment of Alex Epshinsky as the company’s new Chief Financial Officer. Most recently, Epshinsky served as controller at Avenue Therapeu...
09-13 21:11
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Co...
08-10 04:05
The latest update is out from Avenue Therapeutics (ATXI). At the 2024 Annual Me...
06-27 05:17
Avenue Therapeutics press release (NASDAQ:ATXI): Q1 GAAP EPS of $15.40 beats by $24.40. As of March 31, 2024, cash and cash equivalents totaled $3.2 million, compared to $1.8 million at December 31, 2...
05-16 13:35
Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(15.40) per share which missed the analyst consensus estimate of $(9.00) by 71.11 percent. This is a 85.01 percent increase over losses of $(102.75) per
05-15 20:49
Avenue Therapeutics (NASDAQ:ATXI) has filed a prospectus related to the resale of 1.42M shares of common stock. The shares are set to be issued in three tranches, comprised of 689,680 series C warrant...
05-07 03:14
First quarter Diluted Earnings Per Share were $0.98 in 2024 vs. $1.00 in 2023 Guidance Range for 2024 Affirmed at $4.52 to $4.72 per Diluted Share ST. LOUIS, May 2, 2024 /PRNewswire/ -- Amer...
05-03 05:00
Gainers: Collective Audience (CAUD) +93%. Deciphera Pharmaceuticals (DCPH) +72%. HWH International (HWH) +40%. Mullen Automotive (MULN) +32%. SEP Acquisition Corp. (SEPA) +30%. Bit Origin Ltd (BTOG) +...
04-30 00:31
FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.
04-30 00:10
Avenue Therapeutics shares are trading lower by 20.7% during Monday's session. The company announced the exercise of warrants for $4.4 million in gross proceeds.
04-29 22:59